Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

glaxosmithkline biologicals, s.a. - rotavirus humano, vivo atenuado, cepa rix4414 - rotavirus humano, vivo atenuado, cepa rix4414....no menos de 10x6 ccid50

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

glaxosmithkline biologicals s.a. - rotavirus humano, vivo atenuado, cepa rix4414 - rotavirus humano, vivo atenuado, cepa rix4414....no menos de 10 x 6 ccid50

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

glaxosmithkline biologicals, s.a. - virus vivo atenuado de sarampiÓn (cepa schwarz) - virus vivo atenuado de sarampiÓn (cepa schwarz)....no menos de 10 a la 3 ccid 50 / virus vivo atenuado de paperas (cepa rit 4385)....no menos de 10 a la 4.4 ccid 50 / virus vivo atenuado de varicela (cepa oka)....no menos de 10 a la 3.3 pfu / virus vivo atenuado de rubeola (cepa wistar ra 27/3)....no menos de 10 a la 3 ccid 50 / agua para inyecciÓn....0.5 ml (diluyente)

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

merck sharp & dohme corp. - virus vivo atenuado de varicela (cepa oka) - virus vivo atenuado de varicela (cepa oka)....1350ufp mínimo / agua inyectable....0,7ml

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

glaxosmithkline biologicals s.a. - virus vivo atenuado de varicela (cepa oka) - virus vivo atenuado de varicela (cepa oka)....mÍnimo 10³·³ pfu / agua para inyecciÓn....0.5 ml

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

merck sharp & dohme corp. - virus vivo atenuado de varicela (cepa oka) - virus vivo atenuado de varicela (cepa oka)....1350ufp mínimo / agua para inyecciÓn....0.7 ml

United States - English - NLM (National Library of Medicine)

teva women's health, inc. - human adenovirus e serotype 4 strain cl-68578 (unii: fkd3duk39i) (human adenovirus e serotype 4 strain cl-68578 - unii:fkd3duk39i) - human adenovirus e serotype 4 strain cl-68578 32000 [tcid_50] - adenovirus type 4 and type 7 vaccine, live, oral is a vaccine indicated for active immunization for the prevention of febrile acute respiratory disease caused by adenovirus type 4 and type 7. adenovirus type 4 and type 7 vaccine, live, oral is approved for use in military populations 17 through 50 years of age. adenovirus type 4 and type 7 vaccine, live, oral should not be administered to pregnant females [see pregnancy (8.1)] . it is not known whether adenovirus type 4 and type 7 vaccine, live, oral can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. naturally occurring infection with adenoviruses has been associated with fetal harm. pregnancy should be avoided for 6 weeks following receipt of vaccine. severe allergic reaction (e.g., anaphylaxis) to any component of adenovirus type 4 and type 7 vaccine, live, oral is a contraindication [see description (11)]. adenovirus type 4 and type 7 vaccine, live, oral should not be administered to individuals incapable of swa

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - equine rotavirus (inactivated); apramycin; amphotericin b; neomycin; thiomersal - misc. vaccines or anti sera - equine rotavirus (inactivated) biological active 1.0 rp; apramycin antibiotic other 0.0 p; amphotericin b antibiotic other 0.0 p; neomycin antibiotic other 0.0 p; thiomersal mercury other 0.1 % - immunotherapy - horse pregnant - rotavirus enteritis | vaccine | equine rotavirus

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - rotavirus g1 reassortant; rotavirus g2 reassortant; rotavirus g3 reassortant; rotavirus g4 reassortant; rotavirus p1a[8] reassortant - oral solution - rotavirus p1a[8] reassortant 2.3 x10 ^6 iu/dose; rotavirus g2 reassortant 2.8 x10 ^6 iu/dose; rotavirus g4 reassortant 2.0 x10^ 6 iu/dose; rotavirus g3 reassortant 2.2 x10 ^6 iu/dose; rotavirus g1 reassortant 2.2 x10 ^6 iu/dose - rota virus diarrhea vaccines - rotateq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by types g1, g2, g3, g4, and g9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. the first dose of rotateq should be administered between 6 and 12 weeks of age

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - rotavirus, quantity: 1000000 ccid50/dose - oral liquid, suspension - excipient ingredients: sucrose; water for injections; adipic acid; sodium hydroxide; glucose monohydrate; sodium chloride; potassium chloride; magnesium sulfate heptahydrate; ferric nitrate nonahydrate; dibasic sodium phosphate dihydrate; sodium pyruvate; folic acid; calcium pantothenate; inositol; choline chloride; nicotinamide; pyridoxine hydrochloride; thiamine hydrochloride; riboflavine; cystine; tyrosine; arginine; glycine; histidine; isoleucine; leucine; lysine; methionine; phenylalanine; threonine; tryptophan; serine; valine; glutamine; calcium chloride dihydrate; sodium bicarbonate - rotarix is indicated for the prevention of rotavirus gastroenteritis. see section 5.1 pharmacodynamic properties - clinical trials.